Immix Biopharma Attends FDA CEO Forum in Washington DC

Core Points - Immix Biopharma, Inc. was selected to attend an FDA CEO forum led by FDA Commissioner Marty A. Makary on June 5, 2025, focusing on modernizing the regulatory framework for biotechnology and pharmaceutical industries [1][2] - The forum aimed to gather input from industry leaders to enhance patient access to safe and effective therapies, with Immix Biopharma expressing alignment with the FDA's vision for an efficient regulatory environment [2] - Immix Biopharma is a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis, with its lead candidate being NXC-201, a BCMA-targeted CAR-T cell therapy currently in a multi-center study [3] Company Overview - Immix Biopharma, Inc. (Nasdaq: IMMX) is focused on developing cell therapies for serious diseases, particularly AL Amyloidosis [3] - The lead candidate, NXC-201, is being evaluated in the NEXICART-2 study (NCT06097832) for relapsed/refractory AL Amyloidosis, with interim results presented at ASCO 2025 [3] - NXC-201 has received Regenerative Medicine Advanced Therapy (RMAT) designation and Orphan Drug Designation (ODD) from the FDA and EMA [3]